| |
| |
|
| Insider
Information: |
Vessey Rupert |
| Relationship: |
EVP & President, Resea... |
| City: |
Summit |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
55,636 |
|
|
Indirect Shares
|
656 |
|
|
| Direct
Value |
$2,785,705 |
|
|
|
Indirect Value
|
$29,225 |
|
|
| Total
Shares |
56,292 |
|
|
| Total
Value |
$2,814,929 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
6
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 9.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2023-10-26 |
7,885 |
2019-07-01 |
0 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
EVP & President, Resea... |
2023-05-03 |
47,751 |
2023-05-03 |
656 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
79 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TECH |
Techne Corp |
|
– • – |
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
147 |
147 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2019-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
495 |
642 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14,178 |
14,178 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
613 |
613 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., RESEARCH AND EARLY DEV. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
46,749 |
60,927 |
0 |
- |
|
| TECH |
Techne Corp |
|
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
391 |
1,033 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
139 |
79,190 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,859 |
82,091 |
0 |
- |
|
| TECH |
Techne Corp |
|
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
338 |
1,565 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,326 |
123,701 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2023-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,625 |
7,885 |
0 |
- |
|
| CELG |
Celgene Corp |
See remarks |
• – – |
2018-02-02 |
4 |
D |
$99.80 |
$266,765 |
D/D |
(2,673) |
2,950 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
– – – |
2018-05-04 |
4 |
D |
$86.89 |
$133,637 |
D/D |
(1,538) |
4,537 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
• – – |
2018-12-16 |
4 |
D |
$68.20 |
$179,639 |
D/D |
(2,634) |
7,253 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
• – – |
2019-05-02 |
4 |
D |
$95.21 |
$240,977 |
D/D |
(2,531) |
11,453 |
0 |
- |
|
| CELG |
Celgene Corp |
SEE REMARKS |
• – – |
2019-10-31 |
4 |
D |
$108.03 |
$285,631 |
D/D |
(2,644) |
14,178 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., RESEARCH AND EARLY DEV. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,927) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., RESEARCH AND EARLY DEV. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(613) |
0 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2019-12-31 |
4 |
D |
$64.19 |
$507,743 |
D/D |
(7,910) |
22,868 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2020-02-04 |
4 |
D |
$64.29 |
$74,769 |
D/D |
(1,163) |
24,757 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
• – – |
2020-03-01 |
4 |
D |
$59.06 |
$526,992 |
D/D |
(8,923) |
39,183 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-05-01 |
4 |
D |
$60.26 |
$317,811 |
D/D |
(5,274) |
53,776 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-10-30 |
4 |
D |
$58.45 |
$167,109 |
D/D |
(2,859) |
56,721 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-12-02 |
4 |
D |
$62.18 |
$280,183 |
D/D |
(4,506) |
42,208 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2020-12-31 |
4 |
D |
$62.03 |
$822,332 |
D/D |
(13,257) |
54,817 |
0 |
- |
|
79 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
